Originally published in our sister publication, Pain Medicine News.
Tolperisone, a centrally acting oral skeletal muscle relaxant with reported low sedative effect, previously only available outside the United States, is now being evaluated for acute back muscle spasm in U.S. trials.
Randall Kaye, MD, explained how he and his colleagues overcame the obstacle to testing the agent for the U.S. market, by licensing an “ultrapure” form of tolperisone from Sanochemia, a pharmaceutical